BG
Bellevue Group Portfolio holdings
AUM
$4.54B
1-Year Return
22.5%
This Quarter Return
+0.51%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$9.85B
AUM Growth
-$390M
(-3.8%)
Cap. Flow
-$133M
Cap. Flow
% of AUM
-1.35%
Top 10 Holdings %
Top 10 Hldgs %
29.91%
Holding
226
New
13
Increased
56
Reduced
57
Closed
7
Top Buys
| 1 |
Sarepta Therapeutics
SRPT
|
$52.6M |
| 2 |
Revolution Medicines
RVMD
|
$44.1M |
| 3 |
SAGE
Sage Therapeutics
SAGE
|
$37.4M |
| 4 |
Fate Therapeutics
FATE
|
$37M |
| 5 |
AMED
Amedisys
AMED
|
$36.1M |
Top Sells
| 1 |
Moderna
MRNA
|
$314M |
| 2 |
Halozyme
HALO
|
$53M |
| 3 |
Charles River Laboratories
CRL
|
$47.4M |
| 4 |
HRC
HILL-ROM HOLDINGS, INC.
HRC
|
$38M |
| 5 |
Bio-Rad Laboratories Class A
BIO
|
$30.8M |
Sector Composition
| 1 | Healthcare | 96.84% |
| 2 | Industrials | 0.82% |
| 3 | Technology | 0.59% |
| 4 | Financials | 0.04% |
| 5 | Consumer Discretionary | 0.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
151
Quest Diagnostics
DGX
$20.1B
| $1.89M | 0.02% |
+13,000
| New | +$1.89M |
|
152
Xencor
XNCR
$597M
| $1.7M | 0.02% |
52,100
-1,000
| -2% | -$32.7K |
|
153
Arcturus Therapeutics
ARCT
$455M
| $1.65M | 0.02% |
+34,500
| New | +$1.65M |
|
154
Apellis Pharmaceuticals
APLS
$3.62B
| $1.58M | 0.02% |
48,000
| – | – |
|
155
Zoetis
ZTS
$67.9B
| $1.38M | 0.01% |
7,100
| – | – |
|
156
Kura Oncology
KURA
$706M
| $1.08M | 0.01% |
57,500
-500
| -0.9% | -$9.37K |
|
|
CLLS
157
Cellectis
CLLS
$264M
| $1.04M | 0.01% |
82,500
-1,000
| -1% | -$12.6K |
|
158
AC Immune
ACIU
$216M
| $933K | 0.01% |
+139,000
| New | +$933K |
|
159
Kosmos Energy
KOS
$823M
| $864K | 0.01% |
292,000
| – | – |
|
160
Fortinet
FTNT
$58.6B
| $642K | 0.01% |
11,000
| – | – |
|
161
Gartner
IT
$17.9B
| $638K | 0.01% |
2,100
| – | – |
|
162
Dr. Reddy's Laboratories
RDY
$11.8B
| $554K | 0.01% |
42,500
| – | – |
|
163
S&P Global
SPGI
$165B
| $510K | 0.01% |
1,200
| – | – |
|
164
MSCI
MSCI
$43.1B
| $496K | 0.01% |
816
| – | – |
|
165
Intuit
INTU
$186B
| $486K | ﹤0.01% |
900
| – | – |
|
166
McKesson
MCK
$86B
| $484K | ﹤0.01% |
2,430
| – | – |
|
167
Domino's
DPZ
$15.7B
| $477K | ﹤0.01% |
1,000
| – | – |
|
168
Moody's
MCO
$89.6B
| $444K | ﹤0.01% |
1,250
| – | – |
|
169
American Express
AXP
$230B
| $436K | ﹤0.01% |
2,600
| – | – |
|
170
Live Nation Entertainment
LYV
$37.8B
| $428K | ﹤0.01% |
4,700
| – | – |
|
171
Agilent Technologies
A
$36.4B
| $425K | ﹤0.01% |
2,700
| – | – |
|
172
Tradeweb Markets
TW
$26.3B
| $420K | ﹤0.01% |
5,200
| – | – |
|
173
Factset
FDS
$14B
| $415K | ﹤0.01% |
1,050
| – | – |
|
174
TransUnion
TRU
$17.3B
| $415K | ﹤0.01% |
3,696
| – | – |
|
175
Estee Lauder
EL
$31.5B
| $404K | ﹤0.01% |
1,348
| – | – |
|